Research projects
Start of main content
Genomic and transcriptomic study of circulating tumor lymphocytes for the development of biomarkers associated with the response to treatment with inhibitors of the PD-L1 / PD1 pathway in patients with NSCLC
18th national competition for scientific and technical research
Immunotherapy and cancer
Senior Researcher : Ángel Carracedo Álvarez
Research Centre or Institution : Fundación Pública Gallega de Medicina Genómica. Santiago de Compostela.
Abstract
In the transcriptomic analysis we observed a statistically significant difference in the variation of the % of CD8+ T cells in R vs NR between t0 and t1 (p = 0.049; Two-tailed unpaired student T test). A significant decrease was also found in this population of CD8 + cells in non-responders between t0 and t1 (p = 0.001). These data suggest that immunotherapy can revitalize T cell activity, and that this cell population is significantly reduced in patients who do not respond well to treatment.
The expression between PD1+ and PD1- cells in paired samples from the same patient was compared at different times and at different responses. The results show little overlap between the different comparative groups, which is indicative that there are different pathways that mediate response depending on PD1 status, response, or time point of treatment.
Pathway analysis was performed with three different methods: GSEA to determine differentially enriched gene sets between the different phenotypic groups, PANTHER classification to find enriched pathways for the lists of significantly expressed genes, and DAVID classification to find if the lists of significantly expressed or under-expressed genes form gene clusters classified by functional annotations.
Sequencing of ctDNA extracted from 52 plasma samples (25 at t0, 18 at t1, and 9 at t2) and DNA from 18 paired FFPE tumour samples has recently begun. Variants in 197 cancer-related genes may be observed, and it will be possible to compare variants detected in plasma and in the primary tumour of the same patient, observe changes in these variants over time in the same patient, and calculate the tumour mutation burden (TMB) to find a possible link between the number of non-synonymous mutations and the patient's response to treatment.
- Activities related
- Projects related
- News related
- Publications related
-
4
Nov
2022
Session Red Nacional de Metástasis Cerebral (RENACER): Dos años de andadura conjunta. 2ª Asamblea general Madrid, Friday, 4 November 2022, 10:45 hours
-
16
Mar
2023
Conference Nuevas estrategias contra el cáncer: poner el carro delante de los caballos Madrid, Thursday, 16 March 2023, 19:00 hours
-
18
May
2023
Session Riesgo cardiovascular en largos supervivientes de cáncer infantil Madrid, Thursday, 18 May 2023, 9:30 hours
- Tumor microbiome and immune profiles as predictors of treatment response in high-risk non-muscle invasive bladder cancer (MIT-BC Study) 2020 Senior Researcher : Nuria Malats Riera y Ravid Straussman Research Centre or Institution : Centro Nacional de Investigaciones Oncológicas. Madrid y el Weizman Institute of Science. Rehovot
- Spanish National Brain Metastasis Network (RENACER): Implementation, Development and Coordination 2020 Senior Researcher : Eva Ortega Paíno Research Centre or Institution : Centro Nacional de Investigaciones Oncológicas (CNIO). Madrid
- Exploring post-translational regulation of angiogenic and inflammatory-related processes during colorectal cancer progession and differential recurrence 2020 Senior Researcher : Petronila Penela Márquez Research Centre or Institution : Centro de Biología Molecular Severo Ochoa. CSIC - UAM
End of main content